Global diabetes: Rising threat, evolving care.

Rajesh Nair*

Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India

Introduction

Global diabetes prevalence continues to rise significantly, profoundly impacting public health worldwide. The 10th edition of the IDF Diabetes Atlas provides comprehensive estimates of prevalence, incidence, and future burden, highlighting the escalating challenge and stressing the critical need for effective prevention and management strategies globally[2].

Beyond its direct impact, diabetes mellitus is strongly associated with an increased risk of various cancers. An umbrella review has synthesized existing meta-analyses, identifying robust links between diabetes and several cancer types, which emphasizes the profound importance of proactive diabetes management in broader cancer prevention and early detection strategies[5].

In the realm of therapeutic advancements for type 2 diabetes, GLP-1 receptor agonists are increasingly recognized for their beneficial cardiovascular and kidney effects, particularly in patients with chronic kidney disease. A meta-analysis synthesized evidence from multiple trials, demonstrating significant reductions in major adverse cardiovascular events and improvement in kidney outcomes, thereby reinforcing their crucial role beyond just glycemic control[1]. These findings highlight a multi-faceted approach to managing complex diabetes cases.

Similarly, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors provide significant cardiorenal protection for patients with type 2 diabetes and chronic kidney disease. A meta-analysis of randomized controlled trials confirms their role in slowing the progression of kidney disease and reducing cardiovascular events, thus offering a crucial intervention for this high-risk population and demonstrating parallel benefits to GLP-1 agonists[4].

Specific pharmacological agents, such as Semaglutide, demonstrate strong efficacy in achieving both glycemic control and weight reduction in patients afflicted with type 2 diabetes and obesity. This systematic review and meta-analysis consolidates evidence, showing its significant benefits in managing these interrelated conditions, positioning it as a valuable therapeutic option within the expanding treatment landscape[3].

Further advancing treatment paradigms, Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, demonstrates superior efficacy in glycemic control and weight loss for patients with type 2 diabetes. A systematic review and meta-analysis confirms its significant benefits over existing therapies, positioning it as a powerful new treatment option that leverages multiple pathways for enhanced patient outcomes[10].

Understanding the underlying mechanisms of diabetes is equally vital. Recent advancements offer new perspectives on the complex etiology and pathogenesis of Type 1 Diabetes. A comprehensive review explores immunological, genetic, and environmental factors, providing a deeper understanding of disease mechanisms and paving the way for novel preventive and therapeutic strategies targeted at the root causes of the condition[7].

For the practical management of Type 1 Diabetes, Continuous Glucose Monitoring (CGM) has proven to significantly improve glycemic control in adults. A systematic review and meta-analysis highlights that CGM leads to reduced HbA1c levels and lower rates of hypoglycemia, confirming its effectiveness as a standard and essential tool for better diabetes management, enabling real-time adjustments and improved patient quality of life[6].

Building on technological innovations, artificial pancreas systems have significantly advanced the management of Type 1 Diabetes, markedly improving glycemic control and reducing the overall burden of the disease. An updated systematic review and meta-analysis confirms the efficacy and safety of these automated insulin delivery systems, marking them as a transformative technology for patients seeking more stable and less demanding disease control[8].

Despite these advancements, complications of diabetes remain a serious concern. Diabetic retinopathy, for instance, remains a leading cause of blindness globally, with specific epidemiological patterns and risk factors contributing to its prevalence. A review summarizes key risk factors and emphasizes the critical importance of early detection and rigorous prevention strategies, including strict glycemic control, to mitigate its progression and preserve vision[9].

***Correspondence to:** Rajesh Nair, Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India. E-mail: rajesh.nair@aiims.ac.in

Received: 01-Apr-2025, Manuscript No. aaagim-282; **Editor assigned:** 03-Apr-2025, Pre QC No. aaagim-282 *(PQ)*; **Reviewed:** 23-Apr-2025, QC No. aaagim-282; **Revised:** 02-May-2025, Manuscript No. aaagim-282 *(R)*; **Published:** 13-May-2025, DOI: 10.35841/aaagim-9.2.282

Citation: Nair R. Global diabetes: Rising threat, evolving care. aaagim. 2025;09(02):282.

Conclusion

Global diabetes prevalence continues to rise significantly, impacting public health worldwide. The IDF Diabetes Atlas, 10th edition, highlights this escalating challenge, stressing the need for effective prevention and management strategies. Diabetes mellitus is also strongly associated with an increased risk of various cancers, emphasizing the importance of robust diabetes management in cancer prevention.

Significant advancements in treatment options have emerged. GLP-1 receptor agonists are recognized for their beneficial cardiovascular and kidney effects in type 2 diabetes, particularly in chronic kidney disease patients, demonstrating reductions in major adverse cardiovascular events and improved kidney outcomes. Similarly, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, slowing kidney disease progression and reducing cardiovascular events in high-risk populations.

Newer therapies like Semaglutide demonstrate strong efficacy in glycemic control and weight reduction for patients with type 2 diabetes and obesity. Tirzepatide, a dual GIP and GLP-1 receptor agonist, shows superior efficacy in both glycemic control and weight loss. For type 1 diabetes, Continuous Glucose Monitoring (CGM) significantly improves glycemic control by reducing HbA1c and hypoglycemia. Artificial pancreas systems further advance type 1 diabetes management, improving control and reducing disease burden through automated insulin delivery. Diabetic retinopathy remains a leading cause of blindness globally, underscoring the critical need for early detection and strict glycemic control as prevention strategies.

References

1. Hong Y, Chao Z, Hua L. Cardiovascular and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis. *Diabetes Obes Metab.* 2023;25:3161-3172.
2. Hui S, Preeti S, Suman K. IDF Diabetes Atlas, 10th edition: global estimates of diabetes prevalence and incidence and projections of the future burden. *Diabetes Res Clin Pract.* 2022;183:109119.
3. Hao C, Shu D, *Jing X. Efficacy and safety of semaglutide in patients with type* 2 diabetes and obesity: A systematic review and meta-analysis. Diabetes Obes Metab. 2022;24:1314-1324.
4. Jia L, Hong Z, Hong Y. Sodium-Glucose *Cotransporter* 2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Am Heart Assoc. 2020;9:e013401.
5. Kai Y, Hao Z, Jian L. Diabetes mellitus and cancer risk: An umbrella review of meta-analyses of observational studies. *EClinicalMedicine.* 2021;32:100720.
6. Marlies L, Gaby V, *Mark G. The effect of continuous glucose monitoring on glycemic control in adults with type* 1 diabetes: A systematic review and meta-analysis. Diabetes Care. 2021;44:494-503.
7. Romain M, Edouard L, *Michel M. New perspectives on the etiology and pathogenesis of type* 1 diabetes. Autoimmun Rev. 2020;19:102434.
8. Eleni B, Konstantinos K, *Hooda T. Artificial pancreas systems for type* 1 diabetes: an updated systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2021;9:619-631.
9. Fatma A, Abdullah A, Hamdan A. Diabetic retinopathy: Epidemiology, risk factors, and prevention strategies. *Saudi J Ophthalmol.* 2020;34:3-9.
10. Fan Z, Rui H, *Shan L. Efficacy and safety of tirzepatide in patients with type* 2 diabetes: a systematic review and meta-analysis. Ther Adv Endocrinol Metab. 2022;13:20420188221115349.

Citation: *Nair R. Global diabetes: Rising threat, evolving care. aaagim. 2025;09(02):282.*